CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

NCT02697136 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Familial Hypoalphalipoproteinemia

Interventions

DRUG: CER-001
DRUG: Placebo

Sponsor

Cerenis Therapeutics, SA